This is a promotional website intended only for healthcare professionals residing and practising in [insert country]
YESCARTA® (axicabtagene ciloleucel) 0.4 – 2 x 108 cells dispersion for infusion. YESCARTA® is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.*
YESCARTA® (axicabtagene ciloleucel) must be administered at a qualified clinical setting.
*YESCARTA® (axicabtagene ciloleucel) Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/9439/smpc.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur rutrum lorem vel commodo tempor. Proin in ultrices neque. Vivamus accumsan molestie pharetra. Nunc venenatis a arcu ac faucibus. Phasellus auctor lorem nunc, id tempus erat egestas sed. Aenean eget varius libero. Sed gravida luctus mi, eget maximus est venenatis vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur rutrum lorem vel commodo tempor. Proin in ultrices neque. Vivamus accumsan molestie pharetra. Nunc venenatis a arcu ac faucibus. Phasellus auctor lorem nunc, id tempus erat egestas sed. Aenean eget varius libero. Sed gravida luctus mi, eget maximus est venenatis vitae.
Page Vault PromoMats Code: xxx-xxx-xxx
agosto 2020
You are now leaving the Kite, a Gilead Company, promotional website.
You are being directed to